Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,888 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Swedish Orphan Biovitrum AB (publ)의 주요 재무제표는 무엇인가요?
최신 재무제표(Form-10K)에 따르면, Swedish Orphan Biovitrum AB (publ)의 총 자산은 $67,434이며, 순이익입니다.
BIOVF의 주요 재무 비율은 무엇인가요?
Swedish Orphan Biovitrum AB (publ)의 유동비율은 2.26이고, 순이익률은 1.69, 주당 매출은 $80.99입니다.
Swedish Orphan Biovitrum AB (publ)의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Swedish Orphan Biovitrum AB (publ) 주요 수익원은 Haematology이며, 최신 수익 발표에서 수익은 13,370,000,000입니다. 지역별로는 United States이 Swedish Orphan Biovitrum AB (publ)의 주요 시장이며, 수익은 8,148,000,000입니다.
Swedish Orphan Biovitrum AB (publ)은 수익성이 있나요?
예, 최신 재무제표에 따르면 Swedish Orphan Biovitrum AB (publ)의 순이익은 $478입니다.
Swedish Orphan Biovitrum AB (publ)에 부채가 있나요?
예, Swedish Orphan Biovitrum AB (publ)의 부채는 29,717입니다.
Swedish Orphan Biovitrum AB (publ)의 발행 주식은 몇 주인가요?
Swedish Orphan Biovitrum AB (publ)의 총 발행 주식은 345.66주입니다.